ATE478148T1 - Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine - Google Patents

Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine

Info

Publication number
ATE478148T1
ATE478148T1 AT07002409T AT07002409T ATE478148T1 AT E478148 T1 ATE478148 T1 AT E478148T1 AT 07002409 T AT07002409 T AT 07002409T AT 07002409 T AT07002409 T AT 07002409T AT E478148 T1 ATE478148 T1 AT E478148T1
Authority
AT
Austria
Prior art keywords
molecules
acute phase
tif
inhibit
induction
Prior art date
Application number
AT07002409T
Other languages
English (en)
Inventor
Laure Dumoutier
Jean-Christophe Renauld
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Application granted granted Critical
Publication of ATE478148T1 publication Critical patent/ATE478148T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
AT07002409T 2000-07-27 2001-06-27 Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine ATE478148T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62661700A 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
ATE478148T1 true ATE478148T1 (de) 2010-09-15

Family

ID=24511131

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01952260T ATE365801T1 (de) 2000-07-27 2001-06-27 Modulierung durch il-tif/interleukin-21
AT07002409T ATE478148T1 (de) 2000-07-27 2001-06-27 Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01952260T ATE365801T1 (de) 2000-07-27 2001-06-27 Modulierung durch il-tif/interleukin-21

Country Status (9)

Country Link
EP (2) EP1806404B1 (de)
JP (1) JP4113773B2 (de)
CN (3) CN100497628C (de)
AT (2) ATE365801T1 (de)
AU (1) AU7303301A (de)
CA (1) CA2416820A1 (de)
DE (2) DE60129137D1 (de)
ES (1) ES2349312T3 (de)
WO (1) WO2002010393A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
US20030012788A1 (en) 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
US20030023033A1 (en) * 2001-07-26 2003-01-30 Laure Dumoutier Novel class II cytokine receptors and uses thereof
DE60125563T2 (de) * 2000-10-13 2007-10-04 Eli Lilly And Co., Indianapolis Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
AU2003223344B9 (en) 2002-03-22 2009-07-16 Zymogenetics, Inc. Anti-IL-TIF antibodies and methods of using in inflammation
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
US20060281146A1 (en) * 2002-09-11 2006-12-14 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
JP2006525223A (ja) * 2002-10-11 2006-11-09 ノボ・ノルデイスク・エー／エス Ｉｌ２１の使用によるアレルギー症状の治療
US20060177421A1 (en) * 2002-10-11 2006-08-10 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
EP1644415B1 (de) * 2003-06-23 2010-12-01 Genetics Institute, LLC Antikörper gegen interleukin-22 und verwendungen dafür
BRPI0619118A2 (pt) 2005-12-02 2011-09-13 Genentech Inc composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
IT1404858B1 (it) 2011-02-21 2013-12-09 Milano Politecnico Supporto anti-sismico.
EP4200339A4 (de) * 2020-08-05 2025-04-30 Synthekine, Inc. Zusammensetzungen und verfahren im zusammenhang mit rezeptorpaarungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
DE19848683B4 (de) 1998-10-22 2004-05-06 Basf Ag Verbundschichtplatte
WO2000024758A1 (en) * 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF
DK1177312T3 (da) * 1999-04-28 2008-02-25 Genetics Inst Llc Humane GIL-19/AE289-proteiner og polynukleotider kodende derfor
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
AU2253301A (en) * 1999-12-03 2001-06-12 Zymogenetics Inc. Human cytokine receptor

Also Published As

Publication number Publication date
CN100497628C (zh) 2009-06-10
EP1305419B1 (de) 2007-06-27
EP1806404B1 (de) 2010-08-18
EP1806404A1 (de) 2007-07-11
CN100448994C (zh) 2009-01-07
ATE365801T1 (de) 2007-07-15
DE60129137D1 (de) 2007-08-09
CA2416820A1 (en) 2002-02-07
AU7303301A (en) 2002-02-13
WO2002010393A2 (en) 2002-02-07
CN1443241A (zh) 2003-09-17
DE60142861D1 (de) 2010-09-30
WO2002010393A3 (en) 2003-01-30
ES2349312T3 (es) 2010-12-29
JP2004504842A (ja) 2004-02-19
EP1305419A2 (de) 2003-05-02
CN101423551A (zh) 2009-05-06
JP4113773B2 (ja) 2008-07-09
CN1796558A (zh) 2006-07-05

Similar Documents

Publication Publication Date Title
ATE478148T1 (de) Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
CY1112101T1 (el) Νευροτροφικοι παραγοντες
CY1121580T1 (el) ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
SV2008002972A (es) Composiciones, metodos y usos de anticuerpos humanos anti-il-23 ref. cen5117sv
DE60144145D1 (de) Subtilisin-variante
DK3184545T3 (da) Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein
ATE491722T1 (de) Herstellung und reinigung von il-29
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
ATE393222T1 (de) Dcr3 polypeptid, ein tnfr homolog
EP1503795A4 (de) Verwendung von hitzschockproteinen zur verstärkung der wirksamkeit von antikörper-therapeutika
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE408624T1 (de) Verfahren zur reinigung von fsh
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
CY1111371T1 (el) Αντισωματα bag3 για χρηση σε ερευνα, διαγνωση και θεραπεια ασθενειων που σχετιζονται με κυτταρικο θανατο
GEAP202516650A (en) Stabilized pre-fusion hmpv fusion proteins
WO2003065003A3 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
DE69912839D1 (de) Nrihydroxstilbene enthaltende produkte und deren derivate und verfahren zur deren herstellung und ihre verwendung
DE60101851D1 (de) Verfahren zur herstellung von platinmaterial verstärkt mittels fein verteilter oxide.
ATE191568T1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
TR200201119T2 (tr) İnsan alfa1G-C-türü kalsiyum kanalı kodlayan DNA.
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
ATE350387T1 (de) Verfahren zur reinigung von molekülen unter verwendung von unverzweigten alkyldiolen mit einständigen hydroxylgruppen
DE602006009901D1 (de) Verfahren zur herstellung von 7-ethyl-10-hydroxycamptothecin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties